CY2604B2 - Pharmaceutical preparations for drugs of low solubility - Google Patents

Pharmaceutical preparations for drugs of low solubility

Info

Publication number
CY2604B2
CY2604B2 CY0500049A CY0500049A CY2604B2 CY 2604 B2 CY2604 B2 CY 2604B2 CY 0500049 A CY0500049 A CY 0500049A CY 0500049 A CY0500049 A CY 0500049A CY 2604 B2 CY2604 B2 CY 2604B2
Authority
CY
Cyprus
Prior art keywords
pharmaceutical preparations
drugs
low solubility
fatty acids
preparations
Prior art date
Application number
CY0500049A
Other languages
Greek (el)
Inventor
Ulrich Posanski
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6492300&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2604(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY2604B2 publication Critical patent/CY2604B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Η παρούσα εφεύρεση αφορά φαρμακευτικά παρασκευάσματα για δυσδιάλυτες δραστικές ουσίες καθώς και μεθόδους για την παρασκευή των σκευασμάτων αυτών. Ως μέσα διαλυτοποίησης χρησιμοποιούνται πολυγλυκερινικοί εστέρες λιπαρών οξέων ή σορβιτανικοί εστέρες λιπαρών οξέων σε συνδυασμό με λιπόφιλες βοηθητικές ουσίες και μη ιοντικές τασιενεργές ουσίες.The present invention relates to pharmaceutical preparations for poorly soluble active substances as well as methods for the preparation of these preparations. Polyglycerol esters of fatty acids or sorbitan esters of fatty acids are used as solubilizers in combination with lipophilic excipients and non-ionic surfactants.

CY0500049A 1993-07-08 2005-09-08 Pharmaceutical preparations for drugs of low solubility CY2604B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4322826A DE4322826A1 (en) 1993-07-08 1993-07-08 Pharmaceutical preparation

Publications (1)

Publication Number Publication Date
CY2604B2 true CY2604B2 (en) 2010-04-28

Family

ID=6492300

Family Applications (2)

Application Number Title Priority Date Filing Date
CY0200068A CY2308B1 (en) 1993-07-08 2002-12-12 Pharmaceutical compositions for hardly soluble active substances.
CY0500049A CY2604B2 (en) 1993-07-08 2005-09-08 Pharmaceutical preparations for drugs of low solubility

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY0200068A CY2308B1 (en) 1993-07-08 2002-12-12 Pharmaceutical compositions for hardly soluble active substances.

Country Status (24)

Country Link
EP (3) EP0710104B1 (en)
JP (4) JPH08512301A (en)
KR (2) KR100359044B1 (en)
CN (2) CN1313154C (en)
AT (3) ATE261720T1 (en)
AU (2) AU689486B2 (en)
BR (1) BR9407002A (en)
CA (2) CA2166204C (en)
CY (2) CY2308B1 (en)
CZ (1) CZ291401B6 (en)
DE (6) DE4322826A1 (en)
DK (3) DK1092429T3 (en)
ES (3) ES2159564T3 (en)
FI (2) FI116197B (en)
GR (1) GR3036571T3 (en)
HU (2) HU228127B1 (en)
NO (2) NO306929B1 (en)
NZ (2) NZ269552A (en)
PL (1) PL179717B1 (en)
PT (2) PT710103E (en)
RU (1) RU2140291C1 (en)
SI (1) SI1092429T1 (en)
SK (1) SK280615B6 (en)
WO (2) WO1995001785A1 (en)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH686761A5 (en) 1993-05-27 1996-06-28 Sandoz Ag Pharmaceutical formulations.
DE4322826A1 (en) * 1993-07-08 1995-01-12 Galenik Labor Freiburg Gmbh Pharmaceutical preparation
GB9409778D0 (en) 1994-05-16 1994-07-06 Dumex Ltd As Compositions
US6413536B1 (en) * 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US6696413B2 (en) * 1995-06-16 2004-02-24 Hexal Ag Pharmaceutical preparation with cyclosporin A
BE1009856A5 (en) 1995-07-14 1997-10-07 Sandoz Sa Pharmaceutical composition in the form of a solid release including macrolide and a vehicle.
GB9514878D0 (en) * 1995-07-20 1995-09-20 Danbiosyst Uk Vitamin E as a solubilizer for drugs contained in lipid vehicles
GB2317562B (en) * 1995-07-20 1999-08-18 Danbiosyst Uk Lipid vehicle drug delivery composition containing vitamin E
US5597582A (en) * 1995-09-12 1997-01-28 Sanofi Oral gel capsule formulation of 1,2,4-benzotriazine oxides
DE19544507B4 (en) * 1995-11-29 2007-11-15 Novartis Ag Cyclosporin containing preparations
CZ288631B6 (en) * 1996-01-18 2001-08-15 Galena, A. S. Therapeutic preparations containing cyclosporin
CZ288739B6 (en) * 1996-08-01 2001-08-15 Galena, A. S. Cyclosporin containing medicinal preparations
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
GB9705813D0 (en) * 1997-03-20 1997-05-07 Smithkline Beecham Plc Novel compositions
EP0978288A4 (en) * 1997-04-11 2006-07-12 Astellas Pharma Inc Medicinal composition
US6365180B1 (en) * 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
ID25908A (en) * 1998-03-06 2000-11-09 Novartis Ag EMULSION PRACTONCENTRATES CONTAINING CYCLOSPORINE OR MACROLIDES
US7030155B2 (en) 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
GB2344520A (en) * 1998-12-08 2000-06-14 Phares Pharm Res Nv Pharmaceutical carriers comprising lipids and polymers
WO2000040219A1 (en) 1998-12-30 2000-07-13 Dexcel Ltd. Dispersible concentrate for the delivery of cyclosporin
AU2878801A (en) * 1999-10-01 2001-05-10 Natco Pharma Limited An improved pharmaceutical composition and a process for its preparation
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
US20020035107A1 (en) 2000-06-20 2002-03-21 Stefan Henke Highly concentrated stable meloxicam solutions
US20040039036A1 (en) * 2000-11-24 2004-02-26 Yoshimi Hashimoto Water-soluble liquid internal medicine
DE10161077A1 (en) 2001-12-12 2003-06-18 Boehringer Ingelheim Vetmed Highly concentrated stable meloxicam solutions for needleless injection
EP1455810B1 (en) 2001-12-14 2007-06-13 Jagotec Ag Pharmaceutical formulation comprising cyclosporin and use thereof
RU2217170C2 (en) * 2002-02-08 2003-11-27 Мельников Глеб Евгеньевич Disinfecting agent
RU2217169C2 (en) * 2002-02-08 2003-11-27 Мельников Глеб Евгеньевич Disinfecting agent
KR100533458B1 (en) * 2002-07-20 2005-12-07 대화제약 주식회사 Composition for solubilization of paclitaxel and preparation method thereof
GB2391473B (en) * 2002-08-02 2004-07-07 Satishchandra Punambhai Patel Pharmaceutical compositions
US8992980B2 (en) 2002-10-25 2015-03-31 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
FR2850275B1 (en) * 2003-01-24 2005-04-08 Scherer Technologies Inc R P SOFT MACHINE CAPSULES CONTAINING AN ACTIVE ACTIVE SUBSTANCE WITH MASK TASTE
EP1603560A1 (en) 2003-02-06 2005-12-14 Cipla Ltd. Topical immunotherapy and compositions for use therein
JPWO2004073692A1 (en) * 2003-02-18 2006-06-01 山下　伸二 Hard capsule of poorly water-soluble drug
PL2279729T3 (en) * 2003-07-17 2017-02-28 Banner Life Sciences Llc PREPARATIONS ON CONTROLLED RELEASE
EP1568369A1 (en) 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the treatment of respiratory diseases in pigs
TW200616681A (en) * 2004-10-05 2006-06-01 Recordati Ireland Ltd Lercanidipine capsules
GB0425255D0 (en) * 2004-11-16 2004-12-15 Novartis Ag Pharmaceutical composition
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
AU2006275784A1 (en) * 2005-07-28 2007-02-08 Reliant Pharmaceuticals, Inc. Treatment with dihydropyridine calcium channel blockers and omega-3 fatty acids and a combination product thereof
GB0526419D0 (en) * 2005-12-23 2006-02-08 Cyclacel Ltd Formulation
PL2117521T3 (en) 2006-11-03 2012-11-30 Durect Corp Transdermal delivery systems comprising bupivacaine
EP1952807A1 (en) 2007-01-24 2008-08-06 LEK Pharmaceuticals D.D. Sirolimus formulation
ITMI20070720A1 (en) * 2007-04-06 2008-10-07 Monteresearch Srl ORAL COMPOSITIONS CONTAINING TACROLIMUS IN AMORPHOUS FORM
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
ES2685947T3 (en) * 2009-04-10 2018-10-15 Haiyan Qi Anti-aging agents
WO2011046853A1 (en) 2009-10-12 2011-04-21 Boehringer Ingelheim Vetmedica Gmbh Containers for compositions comprising meloxicam
MX2012010077A (en) 2010-03-03 2012-09-12 Boehringer Ingelheim Vetmed Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats.
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
JP5970224B2 (en) 2011-07-11 2016-08-17 株式会社日本自動車部品総合研究所 Spark plug for internal combustion engine
KR20140071913A (en) * 2012-12-04 2014-06-12 삼성정밀화학 주식회사 Food composition and soft capsule including the same
MX2015014181A (en) * 2013-04-09 2016-05-24 Boston Biomedical Inc 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer.
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
HUE053624T2 (en) * 2014-11-07 2021-07-28 Sublimity Therapeutics Ltd Preparations containing cyclosporine
WO2016078481A1 (en) 2014-11-21 2016-05-26 杭州领业医药科技有限公司 Pharmaceutical composition comprising tacrolimus and preparation method thereof
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
AU2017254650A1 (en) 2016-04-20 2018-11-15 Veroscience Llc Composition and method for treating metabolic disorders
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
EP3697418B1 (en) 2017-10-18 2024-07-24 VeroScience LLC Improved bromocriptine formulations
EA202092131A1 (en) * 2018-03-14 2020-11-27 Кэнди Терапьютикс Лимитед NEW PHARMACEUTICAL PREPARATION CONTAINING DUAL ANTAGONISTS OF THE NK-1 / NK-3 RECEPTOR
CN108853044B (en) * 2018-07-06 2020-11-06 郑州明泽医药科技有限公司 Nifedipine sustained release tablet and preparation method thereof
EP3824296A4 (en) 2018-07-20 2022-04-27 Lipocine Inc. LIVER DISEASE
WO2021061818A1 (en) 2019-09-23 2021-04-01 Veroscience Llc Method for inducing tumor regression
EP4090353A4 (en) 2020-01-13 2023-08-09 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
WO2022131656A1 (en) * 2020-12-15 2022-06-23 윤관식 Alkaloid-containing, water-soluble emulsified composition
KR102583074B1 (en) * 2021-01-25 2023-09-25 윤관식 Water-soluble emulsion composition comprising natural polyphenolic compound
KR102712501B1 (en) * 2021-02-26 2024-10-02 윤관식 Water-soluble emulsion composition comprising alkaloids
KR102524312B1 (en) * 2020-12-15 2023-04-21 윤관식 Water-soluble emulsion composition comprising ecdysteroid
JP2024503402A (en) 2021-01-12 2024-01-25 デュレクト コーポレーション Sustained release drug delivery systems and related methods
CN113041236B (en) * 2021-03-23 2023-03-10 广州新济药业科技有限公司 Flurbiprofen cataplasm and preparation method thereof
KR20240173178A (en) * 2023-06-02 2024-12-10 주식회사 지엔티파마 Pharmaceutical composition containing crisdesalazine with improved stability and dissolution rate

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1132518A (en) * 1965-02-18 1968-11-06 Richardson Merrell Inc Medicinal composition
IT1090703B (en) * 1976-12-03 1985-06-26 Scherer Ltd R P IMPROVEMENT IN USEFUL COMPOSITIONS SUCH AS DRUG VEHICLES
GB8903804D0 (en) * 1989-02-20 1989-04-05 Sandoz Ltd Improvements in or relating to organic compounds
GB8630273D0 (en) * 1986-12-18 1987-01-28 Til Medical Ltd Pharmaceutical delivery systems
EP0327280B1 (en) * 1988-01-29 1992-03-18 Sankyo Company Limited Cyclosporin compositions
KR0148748B1 (en) * 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 Pharmaceutical composition containing cyclosporin
JPH0832638B2 (en) * 1989-05-25 1996-03-29 カイロン コーポレイション Adjuvant formulation comprising submicron oil droplet emulsion
ES2119748T3 (en) * 1990-03-23 1998-10-16 Yoshitomi Pharmaceutical PHARMACEUTICAL COMPOSITION CONTAINING A PHARMACEUTICALLY SOLUBLE IN WATER.
GB9113872D0 (en) * 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
JPH0525037A (en) * 1991-07-01 1993-02-02 Upjohn Co:The Oral administrative enzyme sensitive enteric coating
RU2053764C1 (en) * 1991-07-19 1996-02-10 Эгиш Дьедьсердьяр Soft gelatin capsule and method for its production
DE4322826A1 (en) * 1993-07-08 1995-01-12 Galenik Labor Freiburg Gmbh Pharmaceutical preparation

Also Published As

Publication number Publication date
PT1092429E (en) 2004-08-31
HUT73661A (en) 1996-09-30
KR100359044B1 (en) 2003-02-05
JPH08512303A (en) 1996-12-24
CY2308B1 (en) 2003-11-14
ES2218046T3 (en) 2004-11-16
FI960032L (en) 1996-02-09
DE59409787D1 (en) 2001-07-19
NO960069D0 (en) 1996-01-05
AU689486B2 (en) 1998-04-02
FI116197B (en) 2005-10-14
PL179717B1 (en) 2000-10-31
HU9503965D0 (en) 1996-03-28
DE59410365D1 (en) 2004-04-22
FI960032A0 (en) 1996-01-03
HU228127B1 (en) 2012-12-28
NO306929B1 (en) 2000-01-17
AU7345794A (en) 1995-02-06
NO960069L (en) 1996-01-05
CA2164100A1 (en) 1995-01-19
NO960062D0 (en) 1996-01-05
WO1995001786A1 (en) 1995-01-19
EP0710103A1 (en) 1996-05-08
NZ269808A (en) 1996-07-26
DE4494850D2 (en) 1996-08-22
ES2159564T3 (en) 2001-10-16
JP2011153150A (en) 2011-08-11
JPH08512301A (en) 1996-12-24
GR3036571T3 (en) 2001-12-31
ES2124420T3 (en) 1999-02-01
FI960042L (en) 1996-01-04
CN1313154C (en) 2007-05-02
EP1092429B1 (en) 2004-03-17
EP0710103B1 (en) 2001-06-13
CA2166204C (en) 2009-04-14
PT710103E (en) 2001-11-30
DE4494851D2 (en) 1996-12-19
ATE172876T1 (en) 1998-11-15
CN1121853C (en) 2003-09-24
ATE261720T1 (en) 2004-04-15
ATE201985T1 (en) 2001-06-15
FI116714B (en) 2006-02-15
CZ291401B6 (en) 2003-03-12
WO1995001785A1 (en) 1995-01-19
AU7385094A (en) 1995-02-06
DK0710104T3 (en) 1999-07-19
CZ4596A3 (en) 1996-04-17
SI1092429T1 (en) 2004-08-31
JP2009138008A (en) 2009-06-25
PL312255A1 (en) 1996-04-01
SK280615B6 (en) 2000-05-16
EP0710104A1 (en) 1996-05-08
CN1128495A (en) 1996-08-07
HU9503868D0 (en) 1996-02-28
NZ269552A (en) 1996-07-26
EP0710104B1 (en) 1998-11-04
DE59407239D1 (en) 1998-12-10
DK1092429T3 (en) 2004-07-19
NO306763B1 (en) 1999-12-20
HU223073B1 (en) 2004-03-01
KR100386533B1 (en) 2003-08-21
HUT73427A (en) 1996-07-29
EP1092429A1 (en) 2001-04-18
FI960042A0 (en) 1996-01-04
CN1496743A (en) 2004-05-19
SK1996A3 (en) 1997-04-09
DK0710103T3 (en) 2001-09-24
RU2140291C1 (en) 1999-10-27
BR9407002A (en) 1996-09-03
DE4322826A1 (en) 1995-01-12
NO960062L (en) 1996-01-05
CA2166204A1 (en) 1995-01-19

Similar Documents

Publication Publication Date Title
CY2604B2 (en) Pharmaceutical preparations for drugs of low solubility
DE69422163D1 (en) GLYCEROL DERIVATIVE, DEVICE AND PHARMACEUTICAL COMPOSITION
DK0750495T3 (en) Use of a lipophilic surfactant in a pharmaceutical composition
CY1109135T1 (en) PHARMACEUTICAL SOLUTION WHICH INCLUDES RITONAVIR, A SOLVENT (LONG CHAIN OIL FAT) AND WATER
CY1114631T1 (en) PHARMACEUTICAL FORMS OF ECHINOCANDIN Containing surfactants that form a micelle
ES2187062T3 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING PLASMATIC PROTEIN.
BR9405798A (en) Methods for in vivo release of biological material and useful compositions thereof
EP0731712A4 (en) PHYSIOLOGICAL STABILIZED BUTTERIC ACID PREPARATIONS, AND BUTTERIC ACIDS AND DERIVATIVES AS ANTINEOPLASTIC ACTIVE SUBSTANCE
NO20031901D0 (en) Pharmaceutical preparations
PT910353E (en) TRANSDERMIC ADMINISTRATION OF BASIC PHARMACIES USING NAOPOLAR STICKERS AND SOLUBILIZATION AGENTS ACIDS
CY1105896T1 (en) USE OF IDEBENONE FOR THE PROTECTION OF FORMULATIONS
ATE309798T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING CANNABIDIOL DERIVATIVES
ES2171158T3 (en) CRYSTALLIZED OXATIOLAN DERIVATIVES.
MX9201298A (en) NEW CONJUGATES OF PROTEINS WITH POLY ETHYLENE GLYCOL, PROCEDURE FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM.
ATA189395A (en) ORAL PHARMACEUTICAL PREPARATION
FR2627696B1 (en) NEW GALENIC FORM OF FENOFIBRATE
DK0439042T3 (en) Use of pharmaceutical and cosmetic preparations with blend micelles
ES2216055T3 (en) METHODS TO REDUCE OR MAINTAIN REDUCED LEVELS OF LIPIDS IN BLOOD USING PROTEIN COMPOSITIONS OB.
DE69629989D1 (en) PREPARATION FOR EXTERNAL USE FOR TREATING DERMATOS
GR1000617B (en) Applied through the skin pharmaceutical preparations with sterols and / or spirochetalines.
ES2193233T3 (en) USE OF AMIODIPINE, A SALT OF THE SAME OR PHELODIPINE IN COMBINATION WITH AN ACE INHIBITOR IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF NON-ISCHEMICAL CONJUNCTIVE HEART FAILURE.
AR011441A1 (en) DERIVATIVES ESTERS AND AMIDES OF FENYL XANTHINE, PROCESSES FOR ITS PREPARATION, PHARMACEUTICAL FORMULATIONS AND ITS USE IN MEDICINE
ATE226065T1 (en) SOLID INSTANT-RELEASE DOSAGE FORMS AND METHOD FOR THE PRODUCTION THEREOF
ES2169037T3 (en) CONJUGADOS POLIETILENGLICOL-HIRUDINA, ITS PREPARATION PROCEDURE AND ITS USE FOR THE TROMBOSIS TREATMENT.
NO884123D0 (en) STABILIZATION OF THERAPEUTICALLY EFFECTIVE PROTEINS IN PHARMACEUTICAL PREPARATIONS.